Wedbush Lowers Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $36.00

Dianthus Therapeutics (NASDAQ:DNTH) had its price objective decreased by equities researchers at Wedbush from $38.00 to $36.00 in a report issued on Friday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Wedbush’s price target would suggest a potential upside of 30.91% from the company’s previous close.

A number of other research firms have also weighed in on DNTH. Raymond James increased their target price on Dianthus Therapeutics from $34.00 to $51.00 and gave the stock an “outperform” rating in a research note on Thursday, April 18th. HC Wainwright began coverage on Dianthus Therapeutics in a research note on Thursday, May 16th. They issued a “buy” rating and a $40.00 target price on the stock. Baird R W upgraded Dianthus Therapeutics to a “strong-buy” rating in a research note on Friday, July 26th. Lifesci Capital upgraded Dianthus Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. Finally, Cantor Fitzgerald initiated coverage on Dianthus Therapeutics in a research note on Thursday, June 27th. They issued an “overweight” rating on the stock. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Dianthus Therapeutics has an average rating of “Buy” and a consensus price target of $44.71.

Dianthus Therapeutics Price Performance

Shares of NASDAQ DNTH traded up $0.76 during midday trading on Friday, reaching $27.50. 145,393 shares of the stock traded hands, compared to its average volume of 194,359. The stock has a market capitalization of $807.10 million, a PE ratio of -4.72 and a beta of 1.89. Dianthus Therapeutics has a one year low of $6.58 and a one year high of $33.77. The company’s 50 day moving average is $26.34 and its 200 day moving average is $25.05.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.11). The company had revenue of $0.87 million during the quarter, compared to the consensus estimate of $0.48 million. As a group, equities analysts forecast that Dianthus Therapeutics will post -2.18 EPS for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in DNTH. Tower Research Capital LLC TRC bought a new stake in Dianthus Therapeutics during the fourth quarter valued at about $25,000. SG Americas Securities LLC bought a new stake in Dianthus Therapeutics during the second quarter valued at about $112,000. WINTON GROUP Ltd bought a new stake in Dianthus Therapeutics during the second quarter valued at about $265,000. Virtu Financial LLC bought a new stake in Dianthus Therapeutics during the first quarter valued at about $390,000. Finally, Hussman Strategic Advisors Inc. bought a new stake in Dianthus Therapeutics during the first quarter valued at about $630,000. Institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.